TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today opinion article by physician Hamayle Saeed describes being screened for diabetes at a BMI of 23 under guidance for Asian Americans, but not qualifying for a GLP-1 weight-loss drug at BMI 26.5 without another qualifying condition. The piece argues that screening guidance, drug labels and insurer authorization rules apply different definitions of obesity; coverage criteria and access remain dependent on payer policies.
A physician’s account published by MedPage Today on October 31, 2026, describes being screened for diabetes at a body mass index (BMI) of 23 under guidance for Asian Americans, but being denied a GLP-1 medication at a BMI of 26.5 because she did not meet the usual coverage thresholds. The article, by Hamayle Saeed, a South Asian physician, argues that the gap between clinical screening and drug-coverage rules can leave Asian patients assessed as higher-risk without access to treatment based on weight alone.
Saeed writes that her doctor began diabetes screening in line with guidance recognizing that Asian Americans can face diabetes risk at lower BMIs. But when she asked about a GLP-1 receptor agonist, she says she was told she did not qualify: she had a BMI of 26.5, no diabetes, and did not meet the conventional thresholds cited in the article—BMI 30, or 27 with a weight-related condition. Her account concerns her own experience; the article does not identify the specific insurer or provide the denial paperwork.
The opinion contrasts those thresholds with updated clinical guidance. Saeed says the American Diabetes Association’s 2026 Standards of Care advise clinicians to use ethnicity-appropriate cutoffs when confirming excess body fat and specifically identify South Asian patients. She also cites the World Health Organization’s lower BMI action points for Asian populations, 23 and 27.5, and a study of nearly 1.5 million adults in England that found South Asians reached the diabetes risk associated with a BMI of 30 among white adults at a BMI of 23.9.
The article also points to research and policy changes that, Saeed argues, sharpen the discrepancy. It cites a 2026 analysis of 352 GLP-1 trials in which a BMI cutoff of 30 made 41.5% of non-Asian American adults eligible, compared with 13.5% of Asian Americans and 7.2% of Korean adults. A 2025 semaglutide trial in South Korea and Thailand used a local obesity threshold of BMI 25; a post hoc analysis of 68 participants who began below 30 reported greater average weight loss among those assigned semaglutide than placebo. These study results do not establish an individual patient’s eligibility or coverage.
The Gap Between Risk and Coverage
The issue affects how patients move from risk assessment to care. If screening begins at a lower BMI for Asian patients, but medication coverage continues to rely on thresholds developed around other populations, being identified as at risk does not necessarily translate into treatment access. Patients below the standard cutoff may need another qualifying condition, and insurer rules can differ.
Saeed also describes coverage reductions for weight-loss GLP-1s: Medi-Cal dropped coverage in January, and MassHealth followed in July. The article does not detail every plan’s current policy, but it argues that tighter benefits can disproportionately affect people whose eligibility already falls near a boundary. The practical stakes include access to medication, out-of-pocket costs, and whether clinical guidance is reflected in reimbursement decisions.
The article’s argument is not that BMI alone should determine treatment. Rather, it asks whether a single cutoff adequately reflects differences in body composition and disease risk, and whether coverage criteria should account for population-specific evidence. Any change would require decisions by regulators, drug makers and payers, not just clinicians.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
Levoit Core 400S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
How the Thresholds Diverged
BMI is a measure based on height and weight, not a direct measurement of body fat or its distribution. Saeed cites evidence that people of Asian descent may have more visceral fat and less muscle at a given BMI than people of European descent, and that type 2 diabetes can emerge at lower BMI levels in some Asian populations. The World Health Organization set lower action points for Asian populations in 2004; these are used to identify risk, not automatically to determine access to a particular drug.
U.S. GLP-1 eligibility has been shaped by clinical trial enrollment criteria and product indications. Saeed says pivotal trials often used Western BMI definitions, and that prior authorization forms have continued to use the familiar cutoffs of 30 or 27 with a related condition. She notes that 2026 labels for Wegovy (semaglutide) and Zepbound (tirzepatide) describe treatment for adults with obesity, or overweight with a weight-related condition, without stating a numerical BMI in the indication. Insurers may still apply numerical criteria in coverage policies, so label wording alone does not establish a patient’s coverage.
The article also compares U.S. policy with guidance from Britain’s National Institute for Health and Care Excellence. NICE recommends a lower BMI threshold by 2.5 units for several populations, including South Asian and other Asian patients, in its tirzepatide guidance. That comparison does not mean British and American treatment or coverage systems are otherwise equivalent; it illustrates that policy makers can build ethnicity-related adjustments into eligibility rules.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, physician and author of the MedPage Today opinion article
Coverage Rules Still Vary
The article is an opinion piece and personal account, not a national survey of GLP-1 denials. It does not name Saeed’s insurer, provide the full prior authorization decision, or establish how often Asian patients are denied under the criteria she describes. Coverage may vary by plan, indication, drug and state, and a clinical guideline does not by itself require an insurer to cover a medicine.
The cited research also does not settle what BMI threshold should govern every prescription. Trial results in selected participants cannot alone determine long-term benefits, risks, or cost-effectiveness across all Asian populations. The source material does not provide details on the full evidence base behind the 2026 label wording or show whether payers have revised their forms in response. It is also unclear whether the reported state coverage changes apply uniformly to every member or circumstance.
Whether Payers Revise Criteria
The next practical test is whether health plans and public programs change prior authorization criteria to reflect updated clinical guidance and the evidence cited in the article. Patients and clinicians will need to check the current policy for the specific drug, plan and medical indication; label language does not guarantee coverage.
Further trial data, updated professional guidance and payer decisions may clarify whether lower, population-specific thresholds should be used and under what conditions. Saeed’s article does not announce a forthcoming policy change or give a timetable. For now, the reported mismatch remains a question of how clinical risk definitions are translated into coverage rules.
Key Questions
What happened in the report?
Physician Hamayle Saeed described being screened for diabetes at BMI 23 under guidance for Asian Americans, but not qualifying for a GLP-1 medication at BMI 26.5 without another qualifying condition. Her account appeared in a MedPage Today opinion article dated October 31, 2026.
Why can diabetes screening start below BMI 30?
Guidance cited in the article recognizes that some Asian populations can develop diabetes at lower BMI levels. Screening thresholds identify when clinicians should assess risk; they are not the same as drug-coverage requirements.
Does a GLP-1 label guarantee insurance coverage?
No. Saeed says current labels describe eligible conditions without stating a numerical BMI in the indication, while insurers may continue to use BMI cutoffs in prior authorization policies. Coverage depends on the individual plan and circumstances.
What does the cited semaglutide research show?
The article describes a 2025 trial in South Korea and Thailand using a local obesity threshold of BMI 25, plus a post hoc analysis of 68 participants who began below BMI 30. Those findings report weight-loss outcomes in that study group; they do not, by themselves, establish coverage rules or predict an individual’s result.
Source: medpagetoday.com
